The University of Chicago Header Logo

Connection

Mark J. Ratain to Antineoplastic Agents

Back to Details
This is a "connection" page, showing publications Mark J. Ratain has written about Antineoplastic Agents.
Mark J. Ratain
Connection Strength
14.754
Antineoplastic Agents
  1. Special designations and the US Food and Drug Administration's "dual mandate". J Natl Cancer Inst. 2024 Feb 08; 116(2):177-179.
    View in: PubMed
    Score: 0.428
  2. Negative innovation: when patents are bad for patients. Nat Biotechnol. 2021 08; 39(8):914-916.
    View in: PubMed
    Score: 0.360
  3. Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab. Clin Pharmacol Ther. 2021 07; 110(1):29-31.
    View in: PubMed
    Score: 0.342
  4. Interventional Pharmacoeconomics: A Novel Mechanism for Unlocking Value. Clin Pharmacol Ther. 2020 09; 108(3):487-493.
    View in: PubMed
    Score: 0.330
  5. A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting". JAMA Oncol. 2019 12 01; 5(12):1691-1692.
    View in: PubMed
    Score: 0.320
  6. Drug-Drug Interactions With Oral Antineoplastic Agents. JAMA Oncol. 2017 06 01; 3(6):736-738.
    View in: PubMed
    Score: 0.269
  7. Food Effect Studies for Oncology Drug Products. Clin Pharmacol Ther. 2017 May; 101(5):606-612.
    View in: PubMed
    Score: 0.266
  8. Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule. Invest New Drugs. 2017 08; 35(4):471-477.
    View in: PubMed
    Score: 0.263
  9. Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs. J Clin Oncol. 2016 Jan 10; 34(2):103-4.
    View in: PubMed
    Score: 0.243
  10. First-in-human, phase I study of elisidepsin (PM02734) administered as a 30-min or as a 3-hour intravenous infusion every three weeks in patients with advanced solid tumors. Invest New Drugs. 2015 Aug; 33(4):901-10.
    View in: PubMed
    Score: 0.233
  11. Targeted therapies: redefining the primary objective of phase I oncology trials. Nat Rev Clin Oncol. 2014 Sep; 11(9):503-4.
    View in: PubMed
    Score: 0.222
  12. Vemurafenib oral bioavailability: an insoluble problem. J Clin Pharmacol. 2014 Apr; 54(4):375-7.
    View in: PubMed
    Score: 0.216
  13. Challenges in interpreting the evidence for genetic predictors of ototoxicity. Clin Pharmacol Ther. 2013 Dec; 94(6):631-5.
    View in: PubMed
    Score: 0.211
  14. Cancer pharmacogenomics: strategies and challenges. Nat Rev Genet. 2013 Jan; 14(1):23-34.
    View in: PubMed
    Score: 0.197
  15. Importance of food effects for oral oncology drugs. Clin Adv Hematol Oncol. 2012 Jun; 10(6):397-8.
    View in: PubMed
    Score: 0.191
  16. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol. 2012 Apr; 6(2):251-9.
    View in: PubMed
    Score: 0.186
  17. Oncology micro-cap stocks: caveat emptor! J Natl Cancer Inst. 2011 Oct 19; 103(20):1488-9.
    View in: PubMed
    Score: 0.182
  18. Flushing oral oncology drugs down the toilet. J Clin Oncol. 2011 Oct 20; 29(30):3958-9.
    View in: PubMed
    Score: 0.181
  19. Randomized phase II trials: a long-term investment with promising returns. J Natl Cancer Inst. 2011 Jul 20; 103(14):1093-100.
    View in: PubMed
    Score: 0.179
  20. Value-based insurance design in oncology. Lancet Oncol. 2011 Apr; 12(4):321-3.
    View in: PubMed
    Score: 0.176
  21. Current dilemmas in carboplatin dosing. Clin Adv Hematol Oncol. 2011 Mar; 9(3):237-8.
    View in: PubMed
    Score: 0.175
  22. A phase I study of continuous infusion cilengitide in patients with solid tumors. Invest New Drugs. 2012 Apr; 30(2):604-10.
    View in: PubMed
    Score: 0.169
  23. Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products. Clin Cancer Res. 2010 Sep 01; 16(17):4446-51.
    View in: PubMed
    Score: 0.169
  24. Bar the windows but open the door to randomization. J Clin Oncol. 2010 Jul 01; 28(19):3104-6.
    View in: PubMed
    Score: 0.166
  25. Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy. Future Oncol. 2010 Apr; 6(4):563-85.
    View in: PubMed
    Score: 0.164
  26. Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies. Cancer J. 2009 Sep-Oct; 15(5):426-30.
    View in: PubMed
    Score: 0.157
  27. Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol. 2009 Apr 10; 27(11):1800-5.
    View in: PubMed
    Score: 0.152
  28. Biomarkers in early cancer drug development: limited utility. Clin Pharmacol Ther. 2009 Feb; 85(2):134-5.
    View in: PubMed
    Score: 0.151
  29. Pharmacogenetics and pharmacogenomics of anticancer agents. CA Cancer J Clin. 2009 Jan-Feb; 59(1):42-55.
    View in: PubMed
    Score: 0.150
  30. Optimising the design of phase II oncology trials: the importance of randomisation. Eur J Cancer. 2009 Jan; 45(2):275-80.
    View in: PubMed
    Score: 0.150
  31. Genome-wide identification of genetic determinants for the cytotoxicity of perifosine. Hum Genomics. 2008 Sep; 3(1):53-70.
    View in: PubMed
    Score: 0.147
  32. A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours. Eur J Cancer. 2008 Aug; 44(12):1684-92.
    View in: PubMed
    Score: 0.146
  33. Rapamycin: something old, something new, sometimes borrowed and now renewed. Clin Pharmacol Ther. 2007 Oct; 82(4):381-8.
    View in: PubMed
    Score: 0.137
  34. Prescribing oral chemotherapy. BMJ. 2007 Feb 24; 334(7590):376.
    View in: PubMed
    Score: 0.132
  35. Evaluating the activity of temsirolimus in neuroendocrine cancer. Br J Cancer. 2007 Jan 15; 96(1):177; author reply 178-9.
    View in: PubMed
    Score: 0.130
  36. Terminal ballistics of kinase inhibitors: there are no magic bullets. Ann Intern Med. 2006 Nov 07; 145(9):702-3.
    View in: PubMed
    Score: 0.130
  37. The role of pharmacogenetics in cancer therapeutics. Br J Clin Pharmacol. 2006 Jul; 62(1):35-46.
    View in: PubMed
    Score: 0.126
  38. The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res. 2006 Jun 01; 12(11 Pt 2):3612s-6s.
    View in: PubMed
    Score: 0.126
  39. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol. 2006 May 10; 24(14):2151-7.
    View in: PubMed
    Score: 0.125
  40. Measuring response in a post-RECIST world: from black and white to shades of grey. Nat Rev Cancer. 2006 05; 6(5):409-14.
    View in: PubMed
    Score: 0.125
  41. Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006 Jun 01; 24(16):2505-12.
    View in: PubMed
    Score: 0.125
  42. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study. Cancer Chemother Pharmacol. 2006 Jan; 57(2):199-206.
    View in: PubMed
    Score: 0.120
  43. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. J Clin Oncol. 2005 Jun 01; 23(16):3726-32.
    View in: PubMed
    Score: 0.117
  44. Pharmacokinetic variability of anticancer agents. Nat Rev Cancer. 2005 Jun; 5(6):447-58.
    View in: PubMed
    Score: 0.117
  45. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs. 2004 Nov; 22(4):449-58.
    View in: PubMed
    Score: 0.113
  46. Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST. J Clin Oncol. 2004 Nov 15; 22(22):4442-5.
    View in: PubMed
    Score: 0.112
  47. A phase I trial of pharmacokinetic modulation of carboxyamidotriazole (CAI) with ketoconazole in patients with advanced cancer. Cancer Chemother Pharmacol. 2004 Nov; 54(5):377-84.
    View in: PubMed
    Score: 0.110
  48. A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors. Clin Cancer Res. 2004 Jul 01; 10(13):4363-8.
    View in: PubMed
    Score: 0.110
  49. Pharmacogenomics: road to anticancer therapeutics nirvana? Oncogene. 2003 Sep 29; 22(42):6621-8.
    View in: PubMed
    Score: 0.104
  50. Finding the right dose. Clin Adv Hematol Oncol. 2003 Sep; 1(9):517-8, 531.
    View in: PubMed
    Score: 0.104
  51. Randomized discontinuation design: application to cytostatic antineoplastic agents. J Clin Oncol. 2002 Nov 15; 20(22):4478-84.
    View in: PubMed
    Score: 0.098
  52. Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022. Ann Oncol. 2023 01; 34(1):48-60.
    View in: PubMed
    Score: 0.097
  53. Endostatin: are the 2 years up yet? J Clin Oncol. 2002 Sep 15; 20(18):3758-60.
    View in: PubMed
    Score: 0.097
  54. Troxacitabine in patients with refractory leukemia. J Clin Oncol. 2002 Aug 01; 20(15):3356; author reply 3356-7.
    View in: PubMed
    Score: 0.096
  55. Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors. Clin Cancer Res. 2002 Aug; 8(8):2519-23.
    View in: PubMed
    Score: 0.096
  56. A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer. Cancer Chemother Pharmacol. 2002 Jul; 50(1):1-5.
    View in: PubMed
    Score: 0.095
  57. Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. Invest New Drugs. 2022 08; 40(4):762-772.
    View in: PubMed
    Score: 0.095
  58. Update on pharmacogenetics in cancer chemotherapy. Eur J Cancer. 2002 Mar; 38(5):639-44.
    View in: PubMed
    Score: 0.094
  59. Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
    View in: PubMed
    Score: 0.093
  60. Pharmacogenetics in cancer treatment. Annu Rev Med. 2003; 54:437-52.
    View in: PubMed
    Score: 0.092
  61. Clinical trial designs for cytostatic agents. J Clin Oncol. 2001 Jun 15; 19(12):3154-5.
    View in: PubMed
    Score: 0.089
  62. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer. Clin Cancer Res. 2001 May; 7(5):1214-20.
    View in: PubMed
    Score: 0.088
  63. Body surface area as a determinant of pharmacokinetics and drug dosing. Invest New Drugs. 2001 May; 19(2):171-7.
    View in: PubMed
    Score: 0.088
  64. Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan. Drug Metab Dispos. 2001 Apr; 29(4 Pt 2):596-600.
    View in: PubMed
    Score: 0.088
  65. Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer. J Clin Oncol. 2001 Apr 01; 19(7):2084-90.
    View in: PubMed
    Score: 0.088
  66. The Right Dose: From Phase I to Clinical Practice. Am Soc Clin Oncol Educ Book. 2021 Mar; 41:92-106.
    View in: PubMed
    Score: 0.087
  67. Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments. J Clin Oncol. 2021 03 20; 39(9):950-955.
    View in: PubMed
    Score: 0.087
  68. Elimination pathways of [14C]losoxantrone in four cancer patients. Drug Metab Dispos. 2001 Feb; 29(2):96-9.
    View in: PubMed
    Score: 0.087
  69. Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis. Cancer Invest. 2001; 19(1):57-64.
    View in: PubMed
    Score: 0.086
  70. Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change. JAMA Oncol. 2021 01 01; 7(1):25-26.
    View in: PubMed
    Score: 0.086
  71. Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
    View in: PubMed
    Score: 0.085
  72. Development of target-based antineoplastic agents. Invest New Drugs. 2000 Feb; 18(1):7-16.
    View in: PubMed
    Score: 0.081
  73. Phase II randomised discontinuation trial of brivanib in patients with advanced solid tumours. Eur J Cancer. 2019 10; 120:132-139.
    View in: PubMed
    Score: 0.079
  74. Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy. Clin Cancer Res. 2019 10 01; 25(19):5913-5924.
    View in: PubMed
    Score: 0.078
  75. Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998 Sep; 34(10):1493-9.
    View in: PubMed
    Score: 0.073
  76. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? J Clin Oncol. 1998 Jul; 16(7):2297-8.
    View in: PubMed
    Score: 0.073
  77. Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998 Jul; 16(7):2557-67.
    View in: PubMed
    Score: 0.073
  78. Analyzing the clinical actionability of germline pharmacogenomic findings in oncology. Cancer. 2018 07 15; 124(14):3052-3065.
    View in: PubMed
    Score: 0.072
  79. O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings. J Clin Oncol. 1998 May; 16(5):1803-10.
    View in: PubMed
    Score: 0.072
  80. Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071). Cancer Chemother Pharmacol. 1998; 42(1):84-7.
    View in: PubMed
    Score: 0.070
  81. Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30.
    View in: PubMed
    Score: 0.068
  82. Kinetic-Pharmacodynamic Model of Chemotherapy-Induced Peripheral Neuropathy in Patients with Metastatic Breast Cancer Treated with Paclitaxel, Nab-Paclitaxel, or Ixabepilone: CALGB 40502 (Alliance). AAPS J. 2017 09; 19(5):1411-1423.
    View in: PubMed
    Score: 0.068
  83. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol. 1997 Apr; 15(4):1502-10.
    View in: PubMed
    Score: 0.067
  84. Mineralocorticoid insufficiency due to suramin therapy. Cancer. 1996 Dec 01; 78(11):2411-20.
    View in: PubMed
    Score: 0.065
  85. Promising new agents in oncologic treatment. Curr Opin Oncol. 1996 Nov; 8(6):525-34.
    View in: PubMed
    Score: 0.065
  86. Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose. J Clin Oncol. 1996 Sep; 14(9):2622-3.
    View in: PubMed
    Score: 0.064
  87. Data modifications to phase I study of suramin. J Clin Oncol. 1996 Sep; 14(9):2623-4.
    View in: PubMed
    Score: 0.064
  88. Etoposide combined with interferon alfa-2b: novel exploitation of established etoposide pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther. 1996 Mar; 59(3):349-59.
    View in: PubMed
    Score: 0.062
  89. Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender. Pharmacogenetics. 1996 Feb; 6(1):93-101.
    View in: PubMed
    Score: 0.061
  90. Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies. J Clin Oncol. 1996 Jan; 14(1):188-95.
    View in: PubMed
    Score: 0.061
  91. Limited sampling model for area under the concentration time curve of total topotecan. Clin Cancer Res. 1996 Jan; 2(1):43-6.
    View in: PubMed
    Score: 0.061
  92. Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials. Clin Cancer Res. 2016 Feb 01; 22(3):527-9.
    View in: PubMed
    Score: 0.060
  93. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. Pharmacogenomics J. 2016 Feb; 16(1):54-9.
    View in: PubMed
    Score: 0.058
  94. Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10. Drug Metab Dispos. 2015 Jul; 43(7):928-35.
    View in: PubMed
    Score: 0.058
  95. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study. J Clin Oncol. 1995 Mar; 13(3):741-7.
    View in: PubMed
    Score: 0.058
  96. Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion. BMC Cancer. 2015 Feb 18; 15:69.
    View in: PubMed
    Score: 0.057
  97. Encephalopathy is the dose-limiting toxicity of intravenous hepsulfam: results of a phase I trial in patients with advanced hematological malignancies. Cancer Chemother Pharmacol. 1995; 36(3):204-10.
    View in: PubMed
    Score: 0.057
  98. Physician-determined patient risk of toxic effects: impact on enrollment and decision making in phase I cancer trials. J Natl Cancer Inst. 1994 Nov 16; 86(22):1685-93.
    View in: PubMed
    Score: 0.056
  99. Incorporating biomarkers into drug labeling. Clin Adv Hematol Oncol. 2014 Aug; 12(8):525-8.
    View in: PubMed
    Score: 0.055
  100. Conventional dosing of anticancer agents: precisely wrong or just inaccurate? Clin Pharmacol Ther. 2014 Apr; 95(4):361-4.
    View in: PubMed
    Score: 0.054
  101. Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies. Clin Cancer Res. 2014 Mar 15; 20(6):1666-75.
    View in: PubMed
    Score: 0.053
  102. A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics. 2014 Feb; 24(2):129-32.
    View in: PubMed
    Score: 0.053
  103. Phase I and pharmacokinetic study of a new antineoplastic agent: pyrazine diazohydroxide (NSC 361456). Cancer Res. 1994 Jan 01; 54(1):114-9.
    View in: PubMed
    Score: 0.053
  104. Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents. J Natl Cancer Inst. 1993 Oct 20; 85(20):1637-43.
    View in: PubMed
    Score: 0.052
  105. Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs. Clin Cancer Res. 2013 Nov 01; 19(21):6039-43.
    View in: PubMed
    Score: 0.052
  106. Are drug labels static or dynamic? Clin Pharmacol Ther. 2013 Sep; 94(3):302-4.
    View in: PubMed
    Score: 0.052
  107. Preclinical discovery of candidate genes to guide pharmacogenetics during phase I development: the example of the novel anticancer agent ABT-751. Pharmacogenet Genomics. 2013 Jul; 23(7):374-81.
    View in: PubMed
    Score: 0.051
  108. Phase I study of amonafide dosing based on acetylator phenotype. Cancer Res. 1993 May 15; 53(10 Suppl):2304-8.
    View in: PubMed
    Score: 0.051
  109. Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients. Clin Cancer Res. 2013 Jun 01; 19(11):3059-67.
    View in: PubMed
    Score: 0.050
  110. Individualizing dosing of cancer chemotherapy. Semin Oncol. 1993 Feb; 20(1):30-42.
    View in: PubMed
    Score: 0.050
  111. Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients. PLoS One. 2013; 8(1):e54522.
    View in: PubMed
    Score: 0.050
  112. The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance). Pharmacogenet Genomics. 2013 Jan; 23(1):29-33.
    View in: PubMed
    Score: 0.050
  113. Pharmacodynamic-pharmacokinetic relationships and therapeutic drug monitoring. Cancer Surv. 1993; 17:51-78.
    View in: PubMed
    Score: 0.050
  114. Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res. 2012 Dec 29; 12:481.
    View in: PubMed
    Score: 0.050
  115. Therapeutic relevance of pharmacokinetics and pharmacodynamics. Semin Oncol. 1992 Aug; 19(4 Suppl 11):8-13.
    View in: PubMed
    Score: 0.048
  116. Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes. Ann Oncol. 1992 Feb; 3(2):107-11.
    View in: PubMed
    Score: 0.047
  117. Paradoxical relationship between acetylator phenotype and amonafide toxicity. Clin Pharmacol Ther. 1991 Nov; 50(5 Pt 1):573-9.
    View in: PubMed
    Score: 0.046
  118. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011 Jul 01; 29(19):2660-6.
    View in: PubMed
    Score: 0.044
  119. Merrill Jon Egorin, MD, 1948-2010. Clin Pharmacol Ther. 2011 Feb; 89(2):163-5.
    View in: PubMed
    Score: 0.043
  120. Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst. 2010 Nov 17; 102(22):1698-705.
    View in: PubMed
    Score: 0.043
  121. Pharmacodynamics in cancer therapy. J Clin Oncol. 1990 Oct; 8(10):1739-53.
    View in: PubMed
    Score: 0.042
  122. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin Cancer Res. 2009 Oct 01; 15(19):6250-7.
    View in: PubMed
    Score: 0.040
  123. Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma. J Clin Oncol. 2008 Oct 01; 26(28):4572-8.
    View in: PubMed
    Score: 0.037
  124. Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551. Cancer Chemother Pharmacol. 2009 Apr; 63(5):793-8.
    View in: PubMed
    Score: 0.036
  125. A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia. Invest New Drugs. 2008 Aug; 26(4):331-8.
    View in: PubMed
    Score: 0.036
  126. Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making. J Clin Oncol. 2007 Feb 10; 25(5):548-54.
    View in: PubMed
    Score: 0.033
  127. Cancer chemotherapy and skin changes. Ann Intern Med. 1985 Aug; 103(2):303-4.
    View in: PubMed
    Score: 0.030
  128. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480. Cancer. 2004 Nov 15; 101(10):2202-8.
    View in: PubMed
    Score: 0.028
  129. Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study. Clin Cancer Res. 2004 Nov 01; 10(21):7244-51.
    View in: PubMed
    Score: 0.028
  130. Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity. Cancer Res. 2004 Jun 15; 64(12):4353-6.
    View in: PubMed
    Score: 0.027
  131. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma. Cancer. 2004 Jan 01; 100(1):65-71.
    View in: PubMed
    Score: 0.027
  132. Subcutaneously administered recombinant human interleukin-2 and interferon alfa-2a for advanced breast cancer: a phase II study of the Cancer and Leukemia Group B (CALGB 9041). Invest New Drugs. 2004 Jan; 22(1):83-9.
    View in: PubMed
    Score: 0.027
  133. Phase I study of an oral formulation of ZD9331 administered daily for 28 days. J Clin Oncol. 2003 May 01; 21(9):1859-65.
    View in: PubMed
    Score: 0.025
  134. Anticancer drug discovery and development throughout the world. J Clin Oncol. 2002 Sep 15; 20(18 Suppl):47S-59S.
    View in: PubMed
    Score: 0.024
  135. Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480. J Clin Oncol. 2002 Aug 15; 20(16):3369-75.
    View in: PubMed
    Score: 0.024
  136. In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharm Res. 2002 May; 19(5):588-94.
    View in: PubMed
    Score: 0.024
  137. Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient. J Clin Oncol. 2002 Mar 15; 20(6):1434-5.
    View in: PubMed
    Score: 0.023
  138. Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations. J Clin Oncol. 2001 Mar 01; 19(5):1476-84.
    View in: PubMed
    Score: 0.022
  139. Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea. Clin Cancer Res. 2000 Sep; 6(9):3400-5.
    View in: PubMed
    Score: 0.021
  140. A New Liver Expression Quantitative Trait Locus Map From 1,183 Individuals Provides Evidence for Novel Expression Quantitative Trait Loci of Drug Response, Metabolic, and Sex-Biased Phenotypes. Clin Pharmacol Ther. 2020 06; 107(6):1383-1393.
    View in: PubMed
    Score: 0.020
  141. Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance). J Clin Pharmacol. 2020 04; 60(4):444-452.
    View in: PubMed
    Score: 0.020
  142. Anticancer agents targeting signaling molecules and cancer cell environment: challenges for drug development? J Natl Cancer Inst. 1999 Aug 04; 91(15):1281-7.
    View in: PubMed
    Score: 0.020
  143. Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Med. 2018 11; 7(11):5478-5487.
    View in: PubMed
    Score: 0.019
  144. A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer. Ann Oncol. 1998 Oct; 9(10):1085-90.
    View in: PubMed
    Score: 0.018
  145. Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol. 1998 Jul; 39(1):63-73.
    View in: PubMed
    Score: 0.018
  146. Phase II and pharmacodynamic studies of pyrazine diazohydroxide (NSC 361456) in patients with advanced renal and colorectal cancer. Clin Cancer Res. 1998 Apr; 4(4):929-34.
    View in: PubMed
    Score: 0.018
  147. Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood. 1998 Jan 15; 91(2):399-405.
    View in: PubMed
    Score: 0.018
  148. Interleukin-2 fusion protein: an investigational therapy for interleukin-2 receptor expressing malignancies. Eur J Cancer. 1997 Jan; 33 Suppl 1:S34-6.
    View in: PubMed
    Score: 0.016
  149. Keratoacanthomas and skin neoplasms associated with suramin therapy. Arch Dermatol. 1996 Jan; 132(1):96-8.
    View in: PubMed
    Score: 0.015
  150. Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies. Leuk Lymphoma. 1994 Jul; 14(3-4):257-62.
    View in: PubMed
    Score: 0.014
  151. Phase I study of adozelesin administered by 24-hour continuous intravenous infusion. J Natl Cancer Inst. 1994 Mar 02; 86(5):368-72.
    View in: PubMed
    Score: 0.013
  152. Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1993; 31(4):283-8.
    View in: PubMed
    Score: 0.012
  153. Estimation of renal cell carcinoma treatment effects from disease progression modeling. Clin Pharmacol Ther. 2013 Apr; 93(4):345-51.
    View in: PubMed
    Score: 0.012
  154. Balanced translocations involving chromosome bands 11q23 and 21q22 in therapy-related leukemia. Blood. 1992 Apr 01; 79(7):1892-3.
    View in: PubMed
    Score: 0.012
  155. Opportunities and challenges in the development of experimental drug combinations for cancer. J Natl Cancer Inst. 2011 Aug 17; 103(16):1222-6.
    View in: PubMed
    Score: 0.011
  156. Vascular endothelial growth factor pathway. Pharmacogenet Genomics. 2010 May; 20(5):346-9.
    View in: PubMed
    Score: 0.010
  157. Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial. Invest New Drugs. 2011 Jun; 29(3):481-8.
    View in: PubMed
    Score: 0.010
  158. What is the choice of treatment for hairy cell leukemia? J Clin Oncol. 1989 Feb; 7(2):156-8.
    View in: PubMed
    Score: 0.009
  159. The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds. Cancer Chemother Pharmacol. 2009 Apr; 63(5):881-7.
    View in: PubMed
    Score: 0.009
  160. Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma. Am J Hematol. 1988 Jan; 27(1):60-2.
    View in: PubMed
    Score: 0.009
  161. A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients. J Clin Oncol. 1987 Dec; 5(12):1968-76.
    View in: PubMed
    Score: 0.009
  162. A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871. Clin Cancer Res. 2007 Jun 01; 13(11):3302-11.
    View in: PubMed
    Score: 0.008
  163. Durability of responses to interferon alfa-2b in advanced hairy cell leukemia. Blood. 1987 Mar; 69(3):872-7.
    View in: PubMed
    Score: 0.008
  164. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol. 2006 Nov; 31(6):783-5.
    View in: PubMed
    Score: 0.008
  165. Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies. Clin Cancer Res. 2004 Jul 01; 10(13):4406-11.
    View in: PubMed
    Score: 0.007
  166. Perceptions of cancer patients and their physicians involved in phase I trials. J Clin Oncol. 1995 May; 13(5):1062-72.
    View in: PubMed
    Score: 0.004
  167. The treatment of hairy cell leukemia: an update. Leukemia. 1992; 6 Suppl 2:24-7.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.